Preclinical evaluation of MK-8189: A novel phosphodiesterase 10A inhibitor for the treatment of schizophrenia

News
1
4 Likes
2

Copilot wrote it more succintly:

MK-8189 is a selective phosphodiesterase 10A (PDE10A) inhibitor being developed by Merck in collaboration with Royalty Pharma. PDE10A is an enzyme found abundantly in the striatum of the human brain, and it plays a role in the breakdown of second messengers cGMP and cAMP2. Abnormal activity in the striatum is associated with symptoms of schizophrenia, such as psychosis, hallucinations, and delusions.

Key Points about MK-8189:

  • Purpose: MK-8189 is being investigated for the treatment of schizophrenia. It aims to alleviate both dopaminergic and glutamatergic dysfunction, which could help with cognitive impairment and psychosis symptoms2.
  • Clinical Trials: The drug has undergone several Phase 1 trials and is currently in Phase 2 trials to evaluate its efficacy and safety in participants with schizophrenia.
  • Potential Benefits: Preclinical studies suggest that MK-8189 has the potential to improve positive symptoms of schizophrenia and cognitive impairment.
  • Side Effects: Reported side effects have been mild, with significant weight loss observed in some participants compared to weight gain seen with other antipsychotics.
3 Likes